PT  - JOURNAL ARTICLE
AU  - Andrejko, Kristin
AU  - Pry, Jake
AU  - Myers, Jennifer F.
AU  - Jewell, Nicholas P.
AU  - Openshaw, John
AU  - Watt, James
AU  - Jain, Seema
AU  - Lewnard, Joseph A.
AU  - ,
TI  - Early evidence of COVID-19 vaccine effectiveness within the general population of California
AID  - 10.1101/2021.04.08.21255135
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.08.21255135
4099  - http://medrxiv.org/content/early/2021/04/10/2021.04.08.21255135.short
4100  - http://medrxiv.org/content/early/2021/04/10/2021.04.08.21255135.full
AB  - Importance Evidence is needed to determine COVID-19 vaccine effectiveness under real-world conditions of use.Objective To determine the effectiveness of authorized vaccines against COVID-19 in the context of substantial circulation of SARS-CoV-2 variants of concern, and identify vaccine uptake barriers.Design We recruited cases (testing positive) and controls (testing negative) based on SARS-CoV-2 molecular diagnostic test results from 24 February-7 April 2021. Controls were individually matched to cases by age, sex, and geographic region. We identified cases and controls via random sampling within predetermined demographic strata. We conducted enrollment and administered study questionnaires via telephone-based facilitated interviews.Setting Population-based surveillance of all SARS-CoV-2 molecular diagnostic testing reported to the California Department of Public Health. During the study period, 69% of sequenced SARS-CoV-2 isolates in California belonged to variants of concern B.1.1.7, B.1.427, or B.1.429.Participants We enrolled 645 adults aged ≥18y, including 325 cases and 320 controlsExposures We assessed participants’ self-reported history of COVID-19 vaccine receipt (BNT162b2 and mRNA-1273). Individuals were considered fully vaccinated two weeks after second dose receipt.Main Outcomes and Measures The primary endpoint was a positive SARS-CoV-2 molecular test result. For unvaccinated participants, we assessed willingness to receive vaccination, when eligible. We measured vaccine effectiveness via the matched odds ratio of prior vaccination, comparing cases with controls.Results Among 325 cases, 23 (7%) and 13 (4%) received BNT162b2 and mRNA-1273, respectively; 8 (2%) were fully vaccinated with either product. Among 260 controls, 49 (19%) and 49 (19%) received BNT162b2 and mRNA-1273, respectively; 42 (16%) were fully vaccinated with either product. Among fully vaccinated individuals, vaccine effectiveness was 86% (95% confidence interval: 67-94%). Vaccine effectiveness was 66% (–69-93%) and 78% (23-94%) one week following a first and second dose, respectively. Among unvaccinated participants, 39% of those residing in rural regions and 23% of those residing in urban regions reported hesitancy to receive COVID-19 vaccines, when eligible. In contrast, vaccine hesitancy did not significantly differ by age, sex, household income, or race/ethnicity.Conclusions and Relevance Ongoing vaccination efforts are preventing SARS-CoV-2 infection in the general population in California. Vaccine hesitancy presents a barrier to reaching coverage levels needed for herd immunity.Question How effective are mRNA-based vaccines in preventing SARS-CoV-2 infection in the context of general population use?Findings In this test-negative design case-control study, fully immunized individuals experienced 86% protection against SARS-CoV-2 infection. Partial protection was evident following receipt of a first dose, and in the first two weeks after receipt of a second dose. Concerns over vaccine safety or side effects are the most common reason for hesitancy among individuals who have not yet been vaccinated.Meaning The ongoing rollout of mRNA-based vaccines is preventing COVID-19 in the general population, despite widespread circulation of SARS-CoV-2 variants of concern.Competing Interest StatementJAL discloses receipt of grants and honoraria from Pfizer, Inc. unrelated to this work.Funding StatementThe study was supported by the California Department of Public Health. JAL and NPJ received support from NIH/NIAID grant R01-AI14812701. JAL discloses receipt of grants and honoraria from Pfizer, Inc. unrelated to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was granted a non-research determination by the State of California Health and Human Services Agency Committee for the Protection of Human Subjects (project number: 2021-034).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data should be communicated to the California Department of Public Health.